Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Takara Bio Dividend Announcement
• Takara Bio announced a annually dividend of ¥17.00 per ordinary share which will be made payable on 2025-06-01. Ex dividend date: 2025-03-28
• Takara Bio's trailing twelve-month (TTM) dividend yield is 1.62%
• Takara Bio's payout ratio for the trailing twelve months (TTM) is 1886.84%
Takara Bio Dividend History
| Ex-Div date | Dividend amount | Dividend type | Pay date |
|---|---|---|---|
| 2025-03-28 | ¥17.00 | annually | 2025-06-01 |
| 2024-03-28 | ¥17.00 | annually | |
| 2023-03-30 | ¥42.00 | annually | 2023-06-26 |
| 2022-03-30 | ¥30.00 | annually | 2022-06-27 |
| 2021-03-30 | ¥9.00 | annually | 2021-06-25 |
| 2020-03-30 | ¥8.00 | annually | 2020-06-24 |
| 2019-03-27 | ¥7.00 | annually | 2019-06-24 |
| 2018-03-28 | ¥4.50 | annually | 2018-06-25 |
| 2017-03-29 | ¥4.00 | annually | 2017-06-26 |
| 2016-03-29 | ¥1.80 | annually | |
| 2015-03-27 | ¥1.50 | annually | |
| 2014-03-27 | ¥1.20 | annually |
Takara Bio Dividend per year
Takara Bio Dividend growth
Takara Bio Dividend Yield
Takara Bio current trailing twelve-month (TTM) dividend yield is 1.62%. Interested in purchasing Takara Bio stock? Use our calculator to estimate your expected dividend yield:
Takara Bio Financial Ratios
Takara Bio Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Takara Bio stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.